Physician profile
Corrie Berk
NPI 1497299184
$155,389.53
in general payments reported to CMS, 2019-2025
13 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,657 · 2022: $19K · 2023: $10K · 2024: $43K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $35K · Food and Beverage: $8,114 · Consulting Fee: $8,110 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,433.75 |
| Travel and Lodging | $35,301.13 |
| Food and Beverage | $8,114.05 |
| Consulting Fee | $8,110.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $64,424.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $58,310.06 | 2021-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18,695.97 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Ipsen Biopharmaceuticals, INC | $8,645.89 | 2024-2025 | Iqirvo, Bylvay |
| Abbvie INC. | $3,382.40 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $1,194.13 | 2021-2025 | Terlivaz |
| Boston Scientific Corporation | $452.67 | 2021-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Janssen Scientific Affairs, LLC | $100.51 | 2024 | Tremfya |
| Orphalan INC | $53.33 | 2023-2024 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $49.42 | 2024 | Vpriv |
| Intercept Pharmaceuticals, INC. | $36.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $22.60 | 2021 | |
| Mirum Pharmaceuticals, INC. | $21.70 | 2024 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrie Berk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.